In normal, non-stressed cells inducible HSPs are poorly expressed; in contrast, overexpression of HSPs has been reported in many tumours and in some types this is linked with worse prognosis and chemo-resistance. 
Materials and Methods
This work was approved by the Ethics Committee of our institution. Immunodetection of HSP70 and HSP40 was accomplished incubating 30 minutes at room temperature with a peroxidase-conjugated rabbit anti-rat (HSP70) or anti-goat (HSP40) secondary antibody at 1/100 dilution (Jackson ImmunoResearch, West Grove, PA, USA).
PATIENTS AND TISSUE SAMPLES
Internal controls were provided in each case by the reactivity of the accompanying lymphocytes, plasma cells, macrophages or endothelial cells.
The staining of the TMA sections for the different antibodies was independently evaluated by two pathologists (M.G-C. and A.P.) according to previously published criteria. 3, 4, 12-15
Concurrent results in the two cores were essential to be considered suitable for the study. 
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The relationships between the expression of the different markers included in the study were analyzed by Pearson chi-square test and Fisher exact test.
A univariate analysis was performed for each clinical variable and for the tumour expression of the analyzed markers. Actuarial survival curves in terms of OS and DFS were constructed according to the Kaplan-Meier method. Comparison of the survival curves for each variable was performed using the log-rank test and Cox univariate analysis.
A backward multivariate analysis was performed using the Cox proportional hazards model to identify factors that might be of independent significance in influencing OS and DFS. The maximal model was formed by the variables found significant in the univariate analysis.
Proportional hazard assumption was assessed by Schoendfeld residual.
All values were based on 2-tailed statistical analysis, with values of p< 0.05 considered statistically significant. The statistical analyses were performed using the SPSS statistical software package (SPSS Inc, Chicago, IL).
Results

CLINICAL FINDINGS
Briefly, 57.5% of patients were males and 42.5% were females. P53 was expressed in 89.5% of patients and p21 in 96.25%; a significant association between both markers was found (p= 0.015).
Statistical analysis showed direct significant associations of HO1 with p53 (p= 0.006) and p21
(p= 0.005); HSP40 with p53 (p= 0.003), active caspase 9 (p= 0.031) and c-FLIP (p= 0.036);
and HSP70 with active caspase 3 (p= 0.000). A. Santón et al.
SURVIVAL ANALYSIS
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The study was performed in 76 patients from the initial 89 for which adequate clinical and laboratory data from the time of diagnosis, as well as follow-up information were available.
Consistent with previous studies, advanced stage at presentation (≥3) and age 45 years or more were strong prognostic markers associated with worse OS (p= 0.001 and p= 0.006, respectively). Stage 3 or 4 also associated with shorter DFS (p= 0.043). Longer DFS was associated with HSP27-negative status (p= 0.014).
OS
In order to identify independent predictors for OS and DFS, a multivariate analysis was performed including in the model the variables found significant in the univariate analysis. Bai et al (67%) and is lower than those reported by others. 14, 27 However, IHC detection of cleaved PARP was reported only in one work and, contrary to our result, strongly correlated with the expression of active caspase 3.
The major inhibitory molecule that prevents proper caspase 3 activation in HRS cells through the intrinsic pathway is XIAP 4 which was present in our series in 73.4% of cases. However, we did not find any significant association of XIAP or antiapoptotic BCL2 with lack of active caspases 3 or 9. Strikingly, a strong direct association existed between the expression of active caspase 3 and that of HSP70 (p= 0.000). Elevated HSP70 does not preclude the activation of caspase 3 but prevents cleavage of PARP. 10, 28 HSP70 can rescue cells from a latter phase of apoptosis than any known survival-promoting protein and protection by HSP70
has been reported to occur in some cases downstream of caspase 3 activation and cleavage of its substrates. 29 Although functional studies are indeed required, it is tempting to speculate that in HRS cells inhibition of the intrinsic apoptotic pathway may be at least partially attributed to the anti-apoptotic effect of HSP70 expression. activation and PARP processing, we studied the expression of active caspase 9 and also of p53 and its effector p21. Although active caspase 9 was detected in most cHL cases (96.2%), this caspase seems not to be truly functional as suggested by activation of caspase 3 only in half of samples. The functional significance of the association between active caspase 9 and HSP40 in our series can only be speculative, but it might point to the HSP70-HSP40 system as a negative regulator of apoptosis since it is well known that HSP40 works in concert with HSP70, helping to lock in the binding of the chaperone to its protein substrate.
Although we have not directly sequenced p53, its expression in HRS cells was associated with that of p21, which seem to suggest that p53 is functionally active and is able to transactivate the p21 target gene, what would support the presence of wild-type p53. 14, 30 It could be inferred from our study that high levels of probably wild-type p53 may be stabilized by members of the HSP families as it has been described for the HSP70-HSP40 system. 31, 32
This could be supported by the direct association found between HSP40 and p53. HO1 was also associated with p53 and p21; in some HO1 over-expressing cell lines, induction of p21 has been observed and may result in improved resistance to apoptotic stimuli . 33, 34 Concerning the role of HSPs as prognostic markers, in our study multivariate analysis showed 
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